Ambrx Biopharma Inc

AMAM

Valor de mercado US$ 1,77 bi

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction.

With stocks up 200%, you face a dilemma. While you don't want to fight momentum, you also don't want to buy into excessive exuberance and jump into a stock at its top, forced to hold until break-even or sell for a loss down the road.

Here is how Ambrx Biopharma Inc. (AMAM) and HealthEquity (HQY) have performed compared to their sector so far this year.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopharma, Inc. (NasdaqGS: AMAM) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Ambrx will receive $28.00 in cash for each share of Ambrx that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopharma, Inc. (NasdaqGS: AMAM) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Ambrx will receive $28.00 in cash for each share of Ambrx that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

J&J (JNJ) is set to acquire Ambrx Biopharma (AMAM) in an all-cash transaction for $2.0 billion. The transaction will likely close in first-half 2024.

Shares of engineered therapeutics specialist Ambrx Biopharma (NASDAQ: AMAM ) skyrocketed on Monday following a major announcement. Pharmaceutical and medical technology stalwart Johnson & Johnson (NYSE: JNJ ) will buy out the company, which should strengthen its oncology unit.

CNBC's Jim Cramer delivers his daily Mad Dash.

The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.

Shares of Ambrx Biopharma Inc (NASDAQ: AMAM) roughly doubled this morning after Johnson & Johnson (NYSE: JNJ) revealed plans of acquiring the clinical-stage biopharmaceutical company. Details of the JNJ-Ambrx deal Johnson & Johnson is willing to pay about $2.0 billion to buy the Nasdaq-listed firm.